Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
SciSparc Ltd. ( (SPRC) ) has issued an update.
On May 27, 2025, SciSparc Ltd. announced the publication of a Japanese divisional patent for a novel pharmaceutical combination of paracetamol and palmitoylethanolamide (PEA). This innovation aims to enhance pain and fever relief with lower doses and fewer side effects compared to paracetamol alone, potentially offering a safer treatment option for patients worldwide. The announcement marks a significant advancement in pain management, aligning with SciSparc’s focus on cannabinoid-based therapies and strengthening its position in the pharmaceutical industry.
More about SciSparc Ltd.
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company focused on developing therapies for central nervous system disorders and rare diseases. The company is engaged in drug development programs based on cannabinoid pharmaceuticals, including treatments for Tourette Syndrome, Alzheimer’s disease, autism, and status epilepticus. SciSparc also has a subsidiary that sells hemp seed oil-based products on the Amazon Marketplace.
Average Trading Volume: 4,095,500
Technical Sentiment Signal: Sell
Current Market Cap: $3.33M
See more data about SPRC stock on TipRanks’ Stock Analysis page.